

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHIA TAI ENTERPRISES INTERNATIONAL LIMITED

正大企業國際有限公司

(Incorporated in Bermuda with members' limited liability)

(Stock Code: 3839)

PROPOSED CHANGE OF COMPANY NAME

The board of directors (the “Board”) of Chia Tai Enterprises International Limited (the “Company”, together with its subsidiaries, the “Group”) proposes to change the English name of the Company from “Chia Tai Enterprises International Limited” to “CPBIO Holding Company Limited” and the secondary name of the Company in Chinese from “正大企業國際有限公司” to “正大生物控股有限公司” (the “Proposed Change of Company Name”).

CONDITIONS FOR THE PROPOSED CHANGE OF COMPANY NAME

The Proposed Change of Company Name is subject to the satisfaction of the following conditions:

- (i) the passing of a special resolution by the shareholders of the Company (the “Shareholders”) at a general meeting of the Company to approve the Proposed Change of Company Name; and
- (ii) the Proposed Change of Company Name has been approved by the Registrar of Companies in Bermuda.

Subject to the satisfaction of the conditions set out above, the Proposed Change of Company Name will take effect from the date on which the Registrar of Companies in Bermuda enters the new English name and the new secondary name in Chinese of the Company on the register of companies (in place of the existing English name and secondary name of the Company). The Company will then carry out all necessary filing procedures with the Companies Registry in Hong Kong.

REASONS FOR THE PROPOSED CHANGE OF COMPANY NAME

The Group’s revenue is derived principally from its biotech business, including manufacture and sales of animal health products (which are mainly preventive drugs for livestock diseases), and chlortetracycline (which are antibiotics for the prevention and treatment of animal diseases). In recent years, the Group has been strategically broadening its product portfolio to cover related veterinary products, some of which are manufactured and sold by the Group, while others are sourced and traded by the Group.

In light of the above, the Company considers that the original company name no longer adequately reflects the Group’s expertise and strategic focus in its biotech business, particularly in the field of animal health. The proposed new name of the Company will better demonstrate the Group’s strategic direction in driving its future growth through its biotech business, and the Group’s commitment

towards serving the global livestock farming and food industry value chain. Accordingly, the Board considers that the Proposed Change of Company Name is in the best interests of the Company and the Shareholders as a whole.

EFFECT OF THE PROPOSED CHANGE OF COMPANY NAME

The Proposed Change of Company Name will not affect any rights of the Shareholders or the Group's daily business operations and its financial position. All existing share certificates in issue bearing the existing name of the Company shall, after the Proposed Change of Company Name becoming effective, continue to be evidence of legal title to such shares of the Company and the existing share certificates will continue to be valid for trading, settlement, registration and delivery purposes. There will not be any arrangement for free exchange of the existing share certificates for new share certificates bearing the new name of the Company. Once the Proposed Change of Company Name becomes effective, new share certificates will be issued only in the new name of the Company.

In addition, subject to confirmation by The Stock Exchange of Hong Kong Limited (the "Stock Exchange"), the English and Chinese stock short names of the Company for trading in the shares of the Company on the Stock Exchange will also be changed after the Proposed Change of Company Name becomes effective.

The Company will make further announcement(s) on the Proposed Change of Company Name, the new English and Chinese stock short names of the Company for trading of the shares of the Company on the Stock Exchange and other related matters and relevant information as and when appropriate.

GENERAL

A special resolution will be proposed at the annual general meeting of the Company ("AGM") for the Shareholders to consider, and if thought fit, approve, the Proposed Change of Company Name. A circular containing, among other matters, details of the Proposed Change of Company Name, together with a notice of the AGM and the related proxy form will be issued as soon as practicable.

By Order of the Board
Chawalit Na Muangtoun
Director

Hong Kong, 16 March 2026

As at the date of this announcement, the Board comprises Mr. Soopakij Chearavanont (Chairman and Executive Director), Mr. Thirayut Phityaisarakul, Mr. Nopadol Chiaravanont, Mr. Chawalit Na Muangtoun (each an Executive Director), Ms. Kobboon Srichai, Mr. Yoichi Ikezoe (each a Non-executive Director), Mr. Surasak Rounroengrom, Mr. Cheng Yuk Wo, Mr. Edward Ko Ming Tung and Ms. Cheung Marn Kay (each an Independent Non-executive Director).